Abstract
The menopausal transition is associated with several symptoms, for which both non-pharmacological and pharmacological measures are available to provide relief. However, present knowledge indicates that the former is not highly effective, and that the latter, in terms of systemic oestrogen and progestogen-based hormone replacement therapy (HRT), although being effective (e.g. on vasomotor symptoms, bleeding control, bone mineral density, vaginal atrophy and quality of life), can be associated with some caveats. Amongst these are an increased risk for coronary heart disease, breast cancer, venous thromboembolism and stroke.
In recent years, literature has indicated a dose dependency for HRT on some of the caveats, hence authorities (Food and Drug Administration, and the European Medicines Agency) and menopause societies (International Menopause Society and North American Menopause Society) now recommend that women deemed in need of HRT should receive the lowest possible dose without compromising the effect of symptom relief. Estradiol 0.5 mg/norethisterone acetate (NETA) 0.1 mg, despite being a lower dose than conventional hormones, is a compound, among a few other low-dose options, that can be used in such therapy. As a first-line oral option, it has demonstrated its effectiveness (which seems comparable to other compounds), with high tolerability and, apparently, no safety concerns, in a 6-month study. Further long-term clinical trials and observational studies are mandatory in order to capture any potential harm as well as to elucidate this compound’s full potential.
Following a thorough literature search using PubMed and MEDLINE from the earliest publication dates through to January 2008, including results from various types of clinical trials and statements on HRT, we review the rationale for these recommendations. We also review the effects and safety of a novel ‘ultra-low-dose’ oral continuous combined HRT tablet, estradiol 0.5 mg/NETA 0.1 mg.
Similar content being viewed by others
References
United Common Database. Available at: http://unstats.un.org/unsd/cdb/cdb_series_xrxx.asp?series_code=13630. Accessed 10 January 2008.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333.
Topal NB, Ayhan S, Topal U, Bilgin T. Effects of hormone replacement therapy regimens on mammographic breast density: the role of progestins. J Obstet Gynaecol Res. 2006;32:305–308.
Bremnes Y, Ursin G, Bjurstam N, Lund E, Gram IT. Different types of postmenopausal hormone therapy and mammographic density in Norwegian women. Int J Cancer. 2007;120:880–884.
Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996;348:981–983.
Wu O. Postmenopausal hormone replacement therapy and venous thromboembolism. Gend Med. 2005;2(suppl 1):S18–S27.
Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977–980.
Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933–941.
Burger H, Archer D, Barlow D, et al. Practical recommendations for hormone replacement therapy in the peri-and postmenopause. Climacteric. 2004;7:210–216.
Pedersen SH, Pedersen NG, Dalsgaard T, Lund CO, Nilas L, Ottesen B. Different cerebrovascular effects of medroxyprogesterone acetate and norethisterone acetate in the New Zealand white rabbit. Climacteric. 2004;7:12–22.
European Medicines Agency. CHMP guideline on clinical investigations of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. Document ref: EMEA/CHMP/021/97 rev 1. London: EMEA; 13 October 2005. Available at: http://www.tga.gov.au/docs/pdf/euguide/emea/002197enrev1.pdf.
Food and Drug Administration. Guidance for industry. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms. Recommendations for clinical evaluation. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); January 2003.
Board of the International Menopause Society. IMS updated recommendations on postmenopausal hormone therapy. Climacteric. 2007;10:181–194.
North American Menopause Society. Estrogen and progestogen use in peri-and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause. 2007;14:168–182.
Santoro N. The menopause transition: an update. Hum Reprod Update. 2002;8:155–160.
Rödström K, Bengtsson C, Lissner L, Björkelund C. Reproducibility of selfreported menopause age at the 24-year follow-up of a population study of women in Gøteborg, Sweden. Menopause. 2005;12:275–280.
Bengtsson C, Lindquist O, Redvall L. Menstrual status and menopausal age of middle-aged Swedish women. A population study of women in Gøteborg 1968–69 and 1974–75. Acta Obstet Gynecol Scand. 1981;60:269–275.
Hammar M, Berg G, Fåhraeus L, Larsson-Cohn U. Climacteric symptoms in an unselected sample of Swedish women. Maturitas. 1984;6:345–350.
Stearns V, Ullmer López JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet. 2002;360:1851–1861.
Maartens LW, Leusink GL, Knottnerus JA, Smeets CG, Pop VJ. Climacteric complaints in the community. Fam Pract. 2001;18:189–194.
Bromberger JT, Meyer PM, Kravitz HM, et al. Psychologic distress and natural menopause: a multiethnic community study. Am J Public Health. 2001;91:1435–1442.
Lipton RB, Goadsby P, Silberstein SD. Classification and epidemiology of headache. Clin Cornerstone. 1999;1:1–10.
Freeman EW, Sammel MD, Lin H, et al. Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol. 2007;110:230–240.
Woods NF, Smith-DiJulio K, Percival DB, Tao EY, Taylor HJ, Mitchell ES. Symptoms during the menopausal transition and early postmenopause and their relation to endocrine levels over time: observations from the Seattle Midlife Women’s Health Study. J Womens Health. 2007;16:667–677.
Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96:351–358.
Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during midlife due to aging or menopause? Fertil Steril. 2001;76:456–460.
Lindau ST, Schumm LP, Laumann EO, Levinson W, O’Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007;357:762–774.
Avis NE, Kaufert PA, Lock M, McKinlay SM, Vass K. The evolution of menopausal symptoms. Baillieres Clin Endocrinol Metab. 1993;7:17–32.
Kumari M, Stafford M, Marmot M. The menopausal transition was associated in a prospective study with decreased health functioning in women who report menopausal symptoms. J Clin Epidemiol. 2005;58:719–727.
Hardy R, Kuh D. Change in psychological and vasomotor symptom reporting during the menopause. Soc Sci Med. 2002;55:1975–1988.
Marmot MG, Stansfeld S, Patel C, et al. Health inequalities among British civil servants: the Whitehall II study. Lancet. 1991;337:1387–1393.
Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M. Measuring the impact of menopausal symptoms on quality of life. BMJ. 1993;307:836–840.
Berg G, Gottwall T, Hammar M, Lindgren R, Gottgall T. Climacteric symptoms among women aged 60–62 in Linkøping, Sweden, in 1986. Maturitas. 1988;10:193–199.
Rödström K, Bengtsson C, Lissner L, Milsom I, Sundh V, Björkelund C. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause. 2002;9:156–161.
Staropoli CA, Flaws JA, Bush TL, Moulton AW. Predictors of menopausal hot flashes. J Womens Health. 1998;7:1149–1155.
Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulff KH, Flaws JA. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol. 2003;101:264–272.
Li C, Samsioe G, Borgfeldt C, Lidfeldt J, Agardh CD, Nerbrand C. Menopause-related symptoms: what are the background factors? A prospective population-based cohort study of Swedish women (the Women’s Health in Lund Area study). Am J Obstet Gynecol. 2003;189:1646–1653.
Freedman RR. Hot flash trends and mechanisms. Menopause. 2002;9:151–152.
Leal M, Diaz J, Serrano E, Abellan J, Carbonell LF. Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes. Obstet Gynecol. 2000;95:804–809.
Ginsburg J, Hardiman P, O’Reilly B. Peripheral blood flow in menopausal women who have hot flushes and in those who do not. BMJ. 1989;298:1488–1490.
Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol. 1993;168:772–780.
Iosif C, Bekassy Z. Prevalence of genitourinary symptoms in the late menopause. Acta Obstet Gynecol Scand. 1984;63:257–260.
Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286:2815–2822.
Welty FK, Lee KS, Lew NS, Nasca M, Zhou JR. The association between soy nut consumption and decreased menopausal symptoms. J Womens Health. 2007;16:361–369.
Lethaby A, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2007;(4):CD001395.
Grady D. Management of menopausal symptoms. N Engl J Med. 2006;355:2338–2347.
Hammar M, Berg G, Lindgren R. Does physical exercise influence the frequency of postmenopausal hot flushes? Acta Obstet Gynecol Scand. 1990;69:409–412.
Daley A, Macarthur C, Mutrie N, Stokes-Lampard H. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2007(4):CD006108.
Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295:2057–2071.
Speroff L, Gass M, Constantine G, et al. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2008;111:77–87.
Rymer JM. The effects of tibolone. Gynecol Endocrinol. 1998;12:213–220.
Swegle JM, Kelly MW. Tibolone: a unique version of hormone replacement therapy. Ann Pharmacother. 2004;38:874–881.
De Lignieres B, Basdevant A, Thomas G, et al. Biological effects of estradiol-17 in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab. 1986;62:536–541.
O’Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol. 1995;35(suppl):S18–S24.
Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo RA. A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol. 1998;159:1540–1546.
Frenkel Y, Kopernik G, Lazer S, et al. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. Maturitas. 1994;20:31–36.
The Transdermal HRT Investigators Group. A randomized study to compare the effectiveness, tolerability and acceptability of two different transdermal estradiol replacement therapies. Int J Fertil Menopausal Stud. 1993;38:5–11.
Mosekilde L, Beck-Nielsen H, Sørensen OH, et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women-results of the Danish Osteoporosis Prevention Study. Maturitas. 2000;36:181–193.
Christiansen C, Christensen MS, McNair P, Hagen C, Stocklund KE, Transbøl I. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest. 1980;10:273–279.
Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287:2668–2676.
Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004;104:443–451.
Gambacciani M, Cappagli B, Ciaponi M, Pepe A, Vacca F, Genazzani AR. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas. 2008;59:2–6.
Gambacciani M, Ciaponi M, Cappagli B, et al. A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women. Gynecol Endocrinol. 2004;18:9–16.
Prestwood KM, Kenny AM, Unson C, Kulldorff M. The effect of low dose micronized 17ss-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study. J Clin Endocrinol Metab. 2000;85:4462–4469.
Salminen HS, Sääf ME, Johansson SE, Ringertz H, Strender LE. The effect of transvaginal estradiol on bone in aged women: a randomised controlled trial. Maturitas. 2007;57:370–381.
Nathorst-Böös J, Hammar M. Effect on sexual life — a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas. 1997;26:15–20.
Simon JA, Bouchard C, Waldbaum A, et al. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007;109:588–596.
The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14:357–369.
Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol. 2008;111:67–76.
Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas. 2003;44:157–163.
Schneider HPG. The view of the International Menopause Society on the Women’s Health Initiative. Climacteric. 2002;5:211–216.
Naftolin F, Schneider HP, Sturdee D, et al. Guidelines for hormone treatment of women in the menopausal transition and beyond. Climacteric. 2004;7:333–337.
Hilditch JR, Lewis J, Ross AH, et al. A comparison of the effects of oral copjugated equine estrogen and transdermal estradiol-17beta combined with an oral progestin on quality of life in postmenopausal women. Maturitas. 1996;24:177–184.
Zethraeus N, Johannesson M, Henriksson P, Strand RT. The impact of hormone replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol. 1997;104:1191–1195.
Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev. 2008;(1):CD003122.
Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study — a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:1–9.
Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia. 2004;47:1175–1187.
Ferrara A, Karter AJ, Ackerson LM, Liu JY, Selby JV. Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: the Northern California Kaiser Permanente Diabetes Registry. Diabetes Care. 2001;24:1144–1150.
Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975;293:1167–1170.
Manson JE, Martin KA. Postmenopausal hormone-replacement therapy. N Engl J Med. 2001;345:34–40.
Weiderpass E, Baron JA, Adami HO, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet. 1999;353:1824–1828.
King RJ, Whitehead MI. Assessment of the potency of orally administered progestins in women. Fertil Steril. 1986;46:1062–1066.
Kurman RJ, Félix JC, Archer DF, Nanavati N, Arce J, Moyer DL. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol. 2000;96:373–379.
Sturdee DW, Ulrich LG, Barlow DH, et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. BJOG. 2000;107:1392–1400.
Riis BJ, Lehmann HJ, Christiansen C. Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs. A review. Am J Obstet Gynecol. 2002;187:1101–1116.
Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod. 2005;20:2052–2060.
Machens K, Schmidt-Gollwitzer K. Issues to debate on the Women’s Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma? Hum Reprod. 2003;18:1992–1999.
McDonough PG. The randomized world is not without its imperfections: reflections on the Women’s Health Initiative study. Fertil Steril. 2002;78:951–956.
Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women’s Health Initiative randomized controlled trial. Climacteric. 2003;6:302–310.
Clark JH. A critique of Women’s Health Initiative studies (2002–2006). Nucl Recept Signal. 2006;4:e023.
Shapiro S. Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women’s Health Initiative studies. Climacteric. 2006;9:416–420.
Løkkegaard E, Lidegaard O, Møller LN, Agger C, Andreasen AH, Jørgensen T. Hormone replacement therapy in Denmark, 1995–2004. Acta Obstet Gynecol Scand. 2007;86:1342–1351.
Tiihonen MJ, Heikkinen AM, Ahonen RS. Do Finnish women using hormone replacement therapy need more information about risks? Pharm World Sci. 2007;29:635–640.
French LM, Smith MA, Holtrop JS, Holmes-Rovner M. Hormone therapy after the Women’s Health Initiative: a qualitative study. BMC Fam Pract. 2006;7:61.
Pedersen AT, Iversen OE, Løkkegaard E, et al. Impact of recent studies on attitudes and use of hormone therapy among Scandinavian gynaecologists. Acta Obstet Gynecol Scand. 2007;86:1490–1495.
Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465–1477.
Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronaryartery calcification. N Engl J Med. 2007;356:2591–2602.
Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health. 2006;15:35–44.
Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. a meta-analysis. J Gen Intern Med. 2006;21:363–266.
Alexandersen P, Tankó LB, Bagger YZ, Qin G, Christiansen C. The long-term impact of 2–3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric. 2006;9:108–118.
Salpeter SR, Walsh JME, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women. a meta-analysis. J Gen Intern Med. 2004;19:791–804.
Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002;53:605–619.
Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006;116:561–570.
Henttonen AT, Kortelainen ML, Kunnas TA, Nikkari ST. Estrogen receptor-1 genotype is related to coronary intima thickness in young to middle-aged women. Scand J Clin Lab Invest. 2007;67:380–386.
Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712.
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350:1047–1059.
Espié M, Daures JP, Chevallier T, Mares P, Micheletti MC, De-Reilhac P. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Gynecol Endocrinol. 2007;23:391–397.
Durna EM, Heller GZ, Leader LR, Sjoblom P, Eden JA, Wren BG. Breast cancer in premenopausal women: recurrence and survival rates and relationship to hormone replacement therapy. Climacteric. 2004;7:284–291.
Verheul HA, Coelingh-Bennink HJ, Kenemans P, et al. Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies. Maturitas. 2000;36:1–17.
Schuetz F, Diel IJ, Pueschel M, et al. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol. 2007;196:342.e1–e9.
Tamimi RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2007;99:1178–1187.
Ettinger B. Personal perspective on lowdosage estrogen therapy for postmenopausal women. Menopause. 1999;6:273–276.
Erel CT, Elter K, Akman C, et al. Mammographic changes in women receiving tibolone therapy. Fertil Steril. 1998;69:870–875.
Egarter C, Eppel W, Vogel S, Wolf G. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts. Maturitas. 2001;40:165–171.
Colacurci N, Mele D, De-Franciscis P, Costa V, Fortunato N, De-Seta L. Effects of tibolone on the breast. Eur J Obstet Gynecol Reprod Biol. 1998;80:235–238.
Lundström E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol. 2002;186:717–722.
Beral V. Million Women Study Collaborators. Breast cancer and hormonereplacement therapy in the Million Women Study. Lancet. 2003;362:419–427.
Velthuis-Te Wierik EJ, Hendricks PT, Martinez C. Preferential prescribing of tibolone and combined estrogen plus progestogen therapy in postmenopausal women. Menopause. 2007;14:518–527.
Kubista E, Kenemans P, Foidart JM, et al. Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients — design and baseline data ‘LIBERATE’ trial. Breast. 2007;16(suppl 2):182–189.
International klimakteriestudie with breast cancer patients terminated prematurely [press release; in Swedish]. Gothenburg, Sweden: Organon Schering-Plough; 21 May 2007. Available at: http://www.organon.se/news/070521liberate.asp. Accessed 10 January 2008.
Scarabin PY, Oger E, Plu-Bureau G. EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362:428–432.
Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-Progestin Replacement Study (HERS). Circulation. 2001;103:638–642.
Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243–1249.
Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol. 2000;95:726–731.
Kenny AM, Kleppinger A, Wang Y, Prestwood KM. Effects of ultra-low-dose estrogen therapy on muscle and physical function in older women. J Am Geriatr Soc. 2005;53:1973–1977.
Gambacciani M, Genazzani AR. Hormone replacement therapy: the benefits in tailoring the regimen and dose. Maturitas. 2001;40:195–201.
6th IMS Workshop web site. Available at: www.6thimsworkshop.com. Accessed 10 December 2007.
Activella physician insert. Princeton, NJ: Novo Nordisk Inc; 2006. Available at: www.fda.gov/cder/foi/label/2006/020907s009s011lbl.pdf. Accessed 10 January 2008.
Activelle Produktresume [in Swedish]. Bagsværd, Denmark: Novo Nordisk A/S; 2007. Available at: www.lakemedelsverket.se/upload/SPC_PIL/Pdf/humspc/Activelle%2005mg01mg%20filmcoated%20tablet.pdf. Accessed 10 January 2008.
Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric. 2007;10:120–131.
Sturdee DW, Archer DF, Rakov V, Lang E. CHOICE Study investigators. Ultra low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. Climacteric. 2008;11:63–73.
Lundström E, Bygdeson M, Svane G, Azavedo E, von-Schoultz B. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. Climacteric. 2007;10:249–256.
Hammar M, Christau S, Nathorst B, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol. 1998;105:904–911.
Hammar ML, van de Weijer P, Franke HR, et al. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG. 2007;114:1522–1529.
Junkermann H, von-Holst T, Lang E, Rakov V. Influence of different HRT regimens on mammographic density. Maturitas. 2005;50:105–110.
Rozenberg S, Caubel P, Lim PC. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms. Int J Gynaecol Obstet. 2001;72:235–243.
Bruhat M, Rudolf K, Vaheri R, Kainulainen P, Timonen U, Viitanen A. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study. Maturitas. 2001;40:259–271.
Endrikat J, Graeser T, Mellinger U, Ertan K, Holz C. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women. Maturitas. 2007;58:201–207.
Conner P, Svane G, Azavedo E, et al. Mammographic breast density, hormones, and growth factors during continuous combined hormone therapy. Fertil Steril. 2004;81:1617–1623.
Mattsson LA, Skouby S, Rees M, et al. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women. Menopause Int. 2007;13:124–131.
Lee BS, Kang BM, Yoon BK, Choi H, Park HM, Kim JG. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebocontrolled, multicenter study. Maturitas. 2007;57:361–369.
Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar J. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75:1065–1079.
Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril. 2001;75:1080–1087.
Pickar JH, Yeh I, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;76:25–31.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Johansen, O.E., Qvigstad, E. Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg. Adv Therapy 25, 525–551 (2008). https://doi.org/10.1007/s12325-008-0070-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-008-0070-6